NCT00539162 2026-04-16
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
M.D. Anderson Cancer Center
Phase NA Recruiting
Clinical Trials
306 trialsNCT05123807 2026-04-16
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06036810 2026-04-16
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT07303894 2026-04-16
A Study of Isoquercetin in People With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03604315 2026-04-15
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05287451 2026-04-15
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
M.D. Anderson Cancer Center
Phase NA Recruiting
NCT07532434 2026-04-15
A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
Peking University Third Hospital
Recruiting
NCT06305299 2026-04-14
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05183984 2026-04-13
NIRVANA-1
ARCAGY/ GINECO GROUP
Phase 2 Recruiting
NCT05769517 2026-04-13
PROBE-II
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT05887609 2026-04-13
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
Phase 2 Recruiting
NCT06710548 2026-04-13
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT04878094 2026-04-09
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 3 Recruiting
NCT06127446 2026-04-09
The Registry of Genetic Alterations of Taiwan Ovarian Cancer
National Health Research Institutes, Taiwan
Recruiting
NCT06665945 2026-04-09
SENTRY
University of Utah
Recruiting
NCT07282158 2026-04-08
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
Fred Hutchinson Cancer Center
Phase NA Recruiting
NCT04294927 2026-04-06
TUBA-WISP-II
University Medical Center Nijmegen
Phase NA Recruiting
NCT05920798 2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2 Recruiting
NCT05752448 2026-04-03
POSTCARE-O
Baylor College of Medicine
Phase NA Recruiting
NCT05080946 2026-04-01
Using Aspirin to Improve Immunological Features of Ovarian Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Recruiting
NCT06290193 2026-04-01
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07290309 2026-03-31
SURGE
Colorado State University
Phase NA Recruiting
NCT06969833 2026-03-30
BCB-OVAIRE
Centre Oscar Lambret
Phase NA Recruiting
NCT04251052 2026-03-27
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NRG Oncology
Phase NA Recruiting
NCT05142033 2026-03-27
ASAP
Avera McKennan Hospital & University Health Center
Recruiting
NCT07495384 2026-03-27
Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
The First Hospital of Jilin University
Phase NA Recruiting
NCT06447064 2026-03-25
(CLOCS-2)
Imperial College London
Recruiting
NCT05990426 2026-03-24
FAST
Northwestern University
Phase NA Recruiting
NCT06580314 2026-03-24
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
Phase 3 Recruiting
NCT07125209 2026-03-24
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
University of Wisconsin, Madison
Recruiting
NCT04919629 2026-03-23
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT03010124 2026-03-20
OvBIOMark
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Recruiting
NCT04038619 2026-03-20
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT04789694 2026-03-19
PHOCUS
Charles University, Czech Republic
Phase 3 Recruiting
NCT05610735 2026-03-19
Combination Therapy for Recurrent Ovarian Cancer
University of Louisville
Phase 1/2 Recruiting
NCT06412510 2026-03-18
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT06422455 2026-03-18
Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
Phase NA Recruiting
NCT07480785 2026-03-18
TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients
Zhejiang University
Phase NA Recruiting
NCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT06412120 2026-03-16
Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
University of Miami
Phase 4 Recruiting
NCT06483048 2026-03-16
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Mayo Clinic
Phase 1 Recruiting
NCT07469709 2026-03-13
PRO-ACTIVE
Fondazione del Piemonte per l'Oncologia
Recruiting
NCT07050771 2026-03-12
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05952453 2026-03-11
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
University of Alabama at Birmingham
Phase 2 Recruiting
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT04575935 2026-03-05
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT06083844 2026-03-04
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting